Skip to content

Study · Animal study (in vivo) · mouse · 2007

3 results

Biological activity of AC3174, a peptide analog of exendin-4.

Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM

Regulatory peptides11 Jan 2007Cited by 30 (Europe PMC)

PMID17292977 (opens in a new tab)DOI10.1016/j.regpep.2006.12.021 (opens in a new tab)PepBankPUB-17292977
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, exenatide and AC3174 produced comparable glucose lowering.

    In plain wordsIn mice, exenatide and AC3174 lowered glucose by comparable amounts.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMagnitude of glucose lowering
    Study

    mousen: not reported in source

    Non-diabetic C57BL/6 and diabetic db/db mice
    Comparator
    AC3174
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The magnitude of glucose lowering of AC3174 was comparable to exenatide.
    1 context sentence
    Summary · context
    In vivo, AC3174, administered as a single IP injection, significantly decreased plasma glucose concentration and glucose excursion following the administration of an oral glucose challenge in both non-diabetic (C57BL/6) and diabetic db/db mice (P<0.05 vs. vehicle-treated).
  2. 02LabIn vitro (cell-free)Activity measurement

    In RINm5f membranes, exenatide and AC3174 had similar potency for labeled GLP-1 displacement.

    In plain wordsIn lab tests, exenatide and AC3174 displaced labeled GLP-1 with similar potency.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGLP-1 displacement potency
    Study

    n: not reported in source

    RINm5f cell membranes
    Comparator
    AC3174
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In RINm5f cell membranes, the potency of AC3174 for the displacement of [(125)I]GLP-1 and activation of adenylate cyclase was similar to that of exenatide and GLP-1.
  3. 03LabIn vitro (cell-free)Activity measurement

    In RINm5f membranes, exenatide and AC3174 had similar potency for adenylate cyclase activation.

    In plain wordsIn lab tests, exenatide and AC3174 activated adenylate cyclase with similar potency.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAdenylate cyclase activation potency
    Study

    n: not reported in source

    RINm5f cell membranes
    Comparator
    AC3174
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In RINm5f cell membranes, the potency of AC3174 for the displacement of [(125)I]GLP-1 and activation of adenylate cyclase was similar to that of exenatide and GLP-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.